All In Biotech

Drug Trial Radar · NCT01994889

Safety and Efficacy of Tafamidis in Patients With Transthyretin Cardiomyopathy

A MULTICENTER, INTERNATIONAL, PHASE 3, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (PF-06291826) 20 MG OR 80 MG IN COMPARISON TO PLACEBO IN SUBJECTS DIAGNOSED WITH TRANSTHYRETIN CARDIOMYOPATHY (TTR-CM)

Last checked: Nov 20, 2026Latest source record: Apr 24, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 441 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

441

Actual

Start

Dec 9, 2013

Primary completion

Feb 7, 2018

Study completion Feb 7, 2018

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Nov 26, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 3 study will investigate the efficacy, safety and tolerability of an oral daily dose of 20 mg or 80 mg tafamidis meglumine capsules compared to placebo in subjects with either transthyretin genetic variants or wild-type transthyretin resulting in amyloid cardiomyopathy.

Conditions

  • Transthyretin (TTR) Amyloid Cardiomyopathy

Interventions

  • TafamidisDrug

    Tafamidis 20 mg in soft gel capsules administered once a day for 30 months

  • TafamidisDrug

    Tafamidis 80 mg in soft gel capsules administered once a day for 30 months

  • PlaceboDrug

    Placebo in soft gel capsules administered once a day for 30 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Hierarchical Combination of All-Cause Mortality and Frequency of Cardiovascular-Related HospitalizationsTime frame: Baseline up to Month 30

Locations

80 sites in 13 countries. Site status is shown where the registry gives one.

  • The Kirklin Clinic

    Birmingham, Alabama

  • UAB Hospital Department of Pharmacy IDS

    Birmingham, Alabama

  • University Hospital, University of Alabama at Birmingham

    Birmingham, Alabama

  • Mayo Clinic Arizona - Mayo Clinic Speciality Building

    Phoenix, Arizona

  • Mayo Clinic Hospital

    Phoenix, Arizona

  • Mayo Clinic Arizona - Mayo Clinic Building

    Scottsdale, Arizona

  • UCSD Clinical and Translational Research Institute, Investigational Drug Service

    La Jolla, California

  • Altman Clinical Translational Research institute

    La Jolla, California

  • Altman Clinical Translational Research Institute

    La Jolla, California

  • UCSD Sulpizio Cardiovascular Center

    La Jolla, California

  • Cedars-Sinai Medical Center, Investigational Drug Pharmacy Services

    Los Angeles, California

  • Cedars-Sinai Medical Center

    Los Angeles, California

  • Cedars-Sinai Medical Care Foundation

    Los Angeles, California

  • UCSF Cardiovascular Care and Prevention Center

    San Francisco, California

  • Stanford University Hospital and Clinics

    Stanford, California

  • UM Sylvester at Deerfield Beach

    Deerfield Beach, Florida

  • University of Miami Hospital & Clinics

    Miami, Florida

  • Northwestern Medical Group

    Chicago, Illinois

  • Northwestern Memorial Hospital

    Chicago, Illinois

  • Advocate Christ Medical Centre

    Oak Lawn, Illinois

  • Ochsner Medical Center

    New Orleans, Louisiana

  • University of Maryland, School of Medicine

    Baltimore, Maryland

  • Johns Hopkins University

    Baltimore, Maryland

  • The Johns Hopkins Hospital IDS Pharmacy

    Baltimore, Maryland

  • Boston Medical Center - Cardiovascular Center, Outpatient Clinic

    Boston, Massachusetts

  • Boston Medical Center Investigational Pharmacy Services

    Boston, Massachusetts

  • Boston Medical Center

    Boston, Massachusetts

  • Boston University Medical Center General Clinical Research Unit

    Boston, Massachusetts

  • Michigan Medicine,University of Michigan

    Ann Arbor, Michigan

  • Mayo Clinic Pharmacy Research Supp

    Rochester, Minnesota

  • Mayo Clinic

    Rochester, Minnesota

  • Newark Beth Israel Medical Center

    Newark, New Jersey

  • New York University Hospitals

    New York, New York

  • Icahn School of Medicine at Mount Sinai and Mount Sinai Hospital

    New York, New York

  • Mount Sinai Doctors Faculty Practice

    New York, New York

  • The Mount Sinai Hospital Department of Pharmacy

    New York, New York

  • Columbia University Medical Center Research Pharmacy

    New York, New York

  • Columbia University Medical Center/Clinical Cardiovascular Research Laboratory for the Elderly

    New York, New York

  • Duke University Health System

    Durham, North Carolina

  • Cleveland Clinic

    Cleveland, Ohio

Showing 40 of 80 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.